Short answer
Arcturus Therapeutics Holdings Inc. (ARCT) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $2M (down 93.0% year over year) with net income of −$27M.
Q1 2026 key financials · XBRL
- Revenue
- $2M
- −93.0% YoY
- Net income
- −$27M
- −91.6% YoY
- Operating margin
- -1403.7%
- EPS (diluted)
- −$0.95
- −82.7% YoY
Source: XBRL data from the Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 10-Q on SEC EDGAR. USD.
Arcturus Therapeutics Holdings Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added geopolitical risk triggered by ongoing Middle East conflicts and planned regional clinical-site activities
- Middle East conflict exposure expanded to potential disruptions involving operations in Israel
- Regulatory and compliance risk from changing international legal, regulatory, and reimbursement conditions
- Clinical-trial execution risk from disrupted regional operations and supply chains
- International-market risk from geopolitical effects on global and regional markets
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arcturus Therapeutics Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.